BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 April-monn SL, Detjen K, Kirchner P, Bräutigam K, Trippel MA, Marques IJ, Grob T, Statzer C, Maire RS, Kollàr A, Chouchane A, Kunze K, Horst D, Sadowski MC, Schrader J, Mercader N, Marinoni I, Wiedenmann B, Perren A. Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies.. [DOI: 10.1101/2022.12.10.519855] [Reference Citation Analysis]
2 Gulde S, Foscarini A, April-Monn SL, Genio E, Marangelo A, Satam S, Helbling D, Falconi M, Toledo RA, Schrader J, Perren A, Marinoni I, Pellegata NS. Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects. Cancers (Basel) 2022;14. [PMID: 36428573 DOI: 10.3390/cancers14225481] [Reference Citation Analysis]
3 Araujo-castro M. Indications for genetic study in gastro-entero-pancreatic and thoracic neuroendocrine tumors. Endocrinología, Diabetes y Nutrición (English ed ) 2022. [DOI: 10.1016/j.endien.2022.11.014] [Reference Citation Analysis]
4 Raderer M, Kiesewetter B. The NET G3 enigma: dealing with a “new” entity. memo 2022. [DOI: 10.1007/s12254-022-00848-z] [Reference Citation Analysis]
5 Ingenerf M, Kiesl S, Winkelmann M, Auernhammer CJ, Rübenthaler J, Grawe F, Fabritius MP, Ricke J, Schmid-tannwald C. Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters. Biomedicines 2022;10:2618. [DOI: 10.3390/biomedicines10102618] [Reference Citation Analysis]
6 Auernhammer CJ, Pavel ME. Immuntherapie bei neuroendokrinen Tumoren. Onkologie 2022;28:660-666. [DOI: 10.1007/s00761-022-01199-4] [Reference Citation Analysis]
7 Araujo-castro M. Indicaciones de estudio genético en los tumores neuroendocrinos gastro-entero-pancreáticos y torácicos. Endocrinología, Diabetes y Nutrición 2022. [DOI: 10.1016/j.endinu.2022.04.004] [Reference Citation Analysis]
8 Crabtree JS. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2022;12:901435. [DOI: 10.3389/fonc.2022.901435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Que QY, Zhang LC, Bao JQ, Ling SB, Xu X. Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 397-408 [DOI: 10.4240/wjgs.v14.i5.397] [Reference Citation Analysis]
10 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Krieg S, Roderburg C, Fung S, Luedde T, Knoefel WT, Krieg A. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04013-1] [Reference Citation Analysis]
12 Auernhammer CJ, Böck S, Westphalen CB, Beyer L, Spitzweg C. Medikamentöse Systemtherapie bei Neuroendokrinen Neoplasien des GastroEnteropankreatischen Systems. Der Nuklearmediziner 2021;44:326-333. [DOI: 10.1055/a-1556-8264] [Reference Citation Analysis]
13 April-Monn SL, Andreasi V, Schiavo Lena M, Sadowski MC, Kim-Fuchs C, Buri MC, Ketkar A, Maire R, Di Domenico A, Schrader J, Muffatti F, Doglioni C, Partelli S, Falconi M, Perren A, Marinoni I. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers (Basel) 2021;13:5014. [PMID: 34638497 DOI: 10.3390/cancers13195014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Krug S, Michl P. Systemische Therapien neuroendokriner Tumoren und Karzinome. Im Fokus Onkologie 2021;24:28-31. [DOI: 10.1007/s15015-021-3621-1] [Reference Citation Analysis]
15 Jin XF, Spöttl G, Maurer J, Nölting S, Auernhammer CJ. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers (Basel) 2021;13:1485. [PMID: 33807122 DOI: 10.3390/cancers13061485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Marjot T, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW, Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol 2021;18:348-64. [PMID: 33692570 DOI: 10.1038/s41575-021-00426-4] [Cited by in Crossref: 149] [Cited by in F6Publishing: 143] [Article Influence: 74.5] [Reference Citation Analysis]